Please try another search
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company’s principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerative colitis, adult and pediatric crohn’s disease, and fistulising crohn’s disease; GB491 (lerociclib), an oral CDK4/6 inhibitor for treating hormone receptor-positive (HR+)/HER2- breast cancer and is under Phase III clinical trials; and GB492, a stimulator of interferon genes (STING) agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 1/2 clinical trial. Further, it develops GB221, a herceptin (trastuzumab)-mimic HER2 monoclonal antibody (mAb) drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB223, a receptor activator of nuclear factor-B Ligand (RANKL) mAb drug candidate, which is under Phase I clinical trial; and GB261 to treat B-cell non-Hodgkin Lymphoma and is under Phase I Clinical trials. In addition, the company’s product candidates under clinical trials include GB262, GB264, GB267, and GB266 for the treatment of cancer. The company was formerly known as JHBP (CY) Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021. The company was founded in 2007 and is headquartered in Shanghai, China.
Name | Age | Since | Title |
---|---|---|---|
Nuoqing Yi | 49 | 2019 | Chairman of the Board |
Qingqing Yi | - | - | Chairman |
Feng Guo | 51 | 2020 | CEO & Chairman |
Zhijian Chen | - | 2021 | Chairman of Scientific Advisory Board |
Edwin Fung | 58 | 2020 | Independent Non-Executive Director |
Wen Chen | 55 | 2020 | Independent Non-Executive Director |
John R. Zalcberg | - | 2021 | Member of Scientific Advisory Board |
Leonard B. Saltz | - | 2021 | Member of Scientific Advisory Board |
Tieming Yu | 41 | 2024 | Non-Executive Director |
David J. Kerr | - | 2021 | Member of Scientific Advisory Board |
Honghao Zhou | 85 | 2020 | Independent Non-Executive Director |
Yangxin Fu | - | 2021 | Member of Scientific Advisory Board |
Alex A. Adjei | 68 | 2021 | Member of Scientific Advisory Board |
John F. Seymour | - | 2021 | Member of Scientific Advisory Board |
Dong Lyu | 49 | 2021 | Non Executive Director |
Yi Liu | 34 | 2022 | Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review